PCVX
Vaxcyte, Inc.NASDAQHealthcare$58.38-0.21%ClosedMarket Cap: $8.40B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
3.03
P/S
0.00
EV/EBITDA
-11.08
DCF Value
$-0.57
FCF Yield
-7.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-25.9%
ROA
-25.2%
ROIC
-32.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | Infinity% | $-274.3M | $-246.5M | $-1.81 | — |
| FY 2025 | $0.00 | NaN% | $-923.7M | $-766.6M | $-5.63 | — |
| Q3 2025 | $0.00 | NaN% | $-242.4M | $-212.8M | $-1.56 | — |
| Q2 2025 | $0.00 | -Infinity% | $-226.2M | $-166.6M | $-1.22 | — |
| Q1 2025 | $0.00 | NaN% | $-180.8M | $-140.7M | $-1.04 | — |
| Q4 2024 | $0.00 | NaN% | $-162.2M | $-137.1M | $-1.12 | — |
| FY 2024 | $0.00 | NaN% | $-569.5M | $-463.9M | $-3.80 | — |
| Q3 2024 | $0.00 | NaN% | $-139.9M | $-103.1M | $-0.83 | — |
| Q2 2024 | $0.00 | NaN% | $-153.0M | $-128.7M | $-1.10 | — |
| Q1 2024 | $0.00 | NaN% | $-114.5M | $-95.0M | $-0.85 | — |
| Q4 2023 | $0.00 | NaN% | $-196.7M | $-180.8M | $-1.73 | — |
| FY 2023 | $0.00 | NaN% | $-468.0M | $-402.3M | $-4.14 | — |